Our Products

Technetium-99m (Tc-99m) is the most widely used medical radioisotope.  Tc-99m is critical for patients in need of important diagnostic tests and used primarily for medical imaging as well as for medical research.  It is used to diagnose and stage serious medical conditions such as heart disease, cancer, infection and inflammation.  Tc-99m is used in more than 40,000 imaging procedures daily in the United States and at least an equal number of procedures in the rest of the world.  Cardiac imaging represents approximately 80% of those 40,000 imaging procedures performed daily in the United States using Tc-99m.

Recently approved by the U.S. Food and Drug Administration (FDA), NorthStar’s processes for the production of Mo-99 are based on proven and well-established principles, yet mark a significant advancement in current technology. By utilizing state-of-the-art chemical processing to achieve domestic Mo-99 production without the use of any uranium target material, NorthStar’s product meets all appropriate Pharmacopeia standards for Mo-99.

Recently approved by the FDA, NorthStar’s first product is an innovative, high tech isotope separation platform, the RadioGenix^TM System, for use in producing the widely used medical radioisotope technetium-99m (Tc-99m) from non-uranium produced molybdenum-99 (Mo-99). NorthStar’s RadioGenix^TM System is the first and only non-uranium based process for production of technetium-99m (Tc-99m) in the United States in more than 25 years.